PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
OPRA vs. AZN
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between OPRA and AZN is 0.09, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.1

Performance

OPRA vs. AZN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Opera Limited (OPRA) and AstraZeneca PLC (AZN). The values are adjusted to include any dividend payments, if applicable.

-20.00%0.00%20.00%40.00%60.00%80.00%SeptemberOctoberNovemberDecember2025February
74.01%
-12.31%
OPRA
AZN

Key characteristics

Sharpe Ratio

OPRA:

1.87

AZN:

1.17

Sortino Ratio

OPRA:

2.75

AZN:

1.60

Omega Ratio

OPRA:

1.31

AZN:

1.22

Calmar Ratio

OPRA:

1.68

AZN:

0.86

Martin Ratio

OPRA:

8.07

AZN:

1.81

Ulcer Index

OPRA:

12.65%

AZN:

13.19%

Daily Std Dev

OPRA:

54.58%

AZN:

20.35%

Max Drawdown

OPRA:

-72.85%

AZN:

-48.94%

Current Drawdown

OPRA:

-14.89%

AZN:

-15.03%

Fundamentals

Market Cap

OPRA:

$1.88B

AZN:

$225.55B

EPS

OPRA:

$1.80

AZN:

$2.25

PE Ratio

OPRA:

11.81

AZN:

32.32

Total Revenue (TTM)

OPRA:

$347.75M

AZN:

$54.07B

Gross Profit (TTM)

OPRA:

$182.52M

AZN:

$43.87B

EBITDA (TTM)

OPRA:

$184.21M

AZN:

$17.22B

Returns By Period

In the year-to-date period, OPRA achieves a 17.77% return, which is significantly higher than AZN's 13.63% return.


OPRA

YTD

17.77%

1M

22.89%

6M

74.00%

1Y

99.57%

5Y*

31.74%

10Y*

N/A

AZN

YTD

13.63%

1M

13.89%

6M

-12.31%

1Y

23.35%

5Y*

11.96%

10Y*

11.42%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

OPRA vs. AZN — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

OPRA
The Risk-Adjusted Performance Rank of OPRA is 8888
Overall Rank
The Sharpe Ratio Rank of OPRA is 9191
Sharpe Ratio Rank
The Sortino Ratio Rank of OPRA is 8989
Sortino Ratio Rank
The Omega Ratio Rank of OPRA is 8484
Omega Ratio Rank
The Calmar Ratio Rank of OPRA is 8787
Calmar Ratio Rank
The Martin Ratio Rank of OPRA is 8888
Martin Ratio Rank

AZN
The Risk-Adjusted Performance Rank of AZN is 7474
Overall Rank
The Sharpe Ratio Rank of AZN is 8181
Sharpe Ratio Rank
The Sortino Ratio Rank of AZN is 7272
Sortino Ratio Rank
The Omega Ratio Rank of AZN is 7373
Omega Ratio Rank
The Calmar Ratio Rank of AZN is 7676
Calmar Ratio Rank
The Martin Ratio Rank of AZN is 6565
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

OPRA vs. AZN - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Opera Limited (OPRA) and AstraZeneca PLC (AZN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for OPRA, currently valued at 1.87, compared to the broader market-2.000.002.004.001.871.17
The chart of Sortino ratio for OPRA, currently valued at 2.75, compared to the broader market-6.00-4.00-2.000.002.004.006.002.751.60
The chart of Omega ratio for OPRA, currently valued at 1.31, compared to the broader market0.501.001.502.001.311.22
The chart of Calmar ratio for OPRA, currently valued at 1.68, compared to the broader market0.002.004.006.001.680.86
The chart of Martin ratio for OPRA, currently valued at 8.07, compared to the broader market0.0010.0020.0030.008.071.81
OPRA
AZN

The current OPRA Sharpe Ratio is 1.87, which is higher than the AZN Sharpe Ratio of 1.17. The chart below compares the historical Sharpe Ratios of OPRA and AZN, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.000.501.001.502.00SeptemberOctoberNovemberDecember2025February
1.87
1.17
OPRA
AZN

Dividends

OPRA vs. AZN - Dividend Comparison

OPRA's dividend yield for the trailing twelve months is around 3.66%, more than AZN's 1.99% yield.


TTM20242023202220212020201920182017201620152014
OPRA
Opera Limited
3.66%4.22%9.07%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
AZN
AstraZeneca PLC
1.99%2.27%2.15%2.14%2.40%2.80%2.81%3.61%3.95%5.01%4.06%3.98%

Drawdowns

OPRA vs. AZN - Drawdown Comparison

The maximum OPRA drawdown since its inception was -72.85%, which is greater than AZN's maximum drawdown of -48.94%. Use the drawdown chart below to compare losses from any high point for OPRA and AZN. For additional features, visit the drawdowns tool.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2025February
-14.89%
-15.03%
OPRA
AZN

Volatility

OPRA vs. AZN - Volatility Comparison

Opera Limited (OPRA) has a higher volatility of 16.75% compared to AstraZeneca PLC (AZN) at 5.47%. This indicates that OPRA's price experiences larger fluctuations and is considered to be riskier than AZN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%SeptemberOctoberNovemberDecember2025February
16.75%
5.47%
OPRA
AZN

Financials

OPRA vs. AZN - Financials Comparison

This section allows you to compare key financial metrics between Opera Limited and AstraZeneca PLC. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab